(Reuters) – Canada’s health department said on Wednesday that it has updated the product label for AstraZeneca Plc’s COVID-19 vaccine to provide information on “very rare reports of blood clots associated with low levels of blood platelets.”
Health Canada continues to back the vaccine, saying that it had not received any reports of these blood clots to date.
Canada, which is using AstraZeneca doses made at the Serum Institute of India, has received 500,000 doses and expects to get 1.5 million more by May.
(Reporting by Shubham Kalia in Bengaluru, Editing by Sherry Jacob-Phillips)
